The current generation of WHO-recommended malaria vaccines, RTS,S and R21, employs a pre-erythrocytic strategy, focusing on generating an immune response against the parasite before it can cause clinical disease. This approach targets the sporozoite, the form of the parasite transmitted to humans by the mosquito bite, specifically the Circumsporozoite Protein (CSP) found on its surface. The...